Filing Details

Accession Number:
0001209191-19-049534
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-13 18:52:56
Reporting Period:
2019-09-12
Accepted Time:
2019-09-13 18:52:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492426 Horizon Therapeutics Public Ltd Co HZNP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1485417 Samuel James Shannon C/O Horizon Therapeutics Plc
Connaught House, 1St Fl, 1 Burlington Rd
Dublin L2 4
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-09-12 15,500 $12.19 15,500 No 4 M Direct
Ordinary Shares Disposition 2019-09-12 15,500 $26.59 0 No 4 S Direct
Ordinary Shares Acquisiton 2019-09-13 9,500 $12.19 9,500 No 4 M Direct
Ordinary Shares Disposition 2019-09-13 9,500 $26.19 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2019-09-12 15,500 $0.00 15,500 $12.19
Ordinary Shares Stock Option (Right to Buy) Disposition 2019-09-13 9,500 $0.00 9,500 $12.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
36,732 2027-08-01 No 4 M Direct
27,232 2027-08-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 19,272 Indirect By Trust
Footnotes
  1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.49 to $26.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.18 to $26.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The 52,232 shares originally subject to the option vest in 36 equal monthly installments from the date of grant (August 2, 2017).